Aflibercept biosimilar (Zaklady)

阿柏西普生物类似药（Zaklady）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameAflibercept biosimilar (Zaklady)
Drug Alias NameVgenfliSDC411SDC-411
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitorsPlacental Growth Factor inhibitors
TargetsVascular endothelial growth factor APlacental Growth Factor
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[6] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/08/14
Country/TerritoryEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZaklady Farmaceutyczne Polpharma SA
China Registration ClassN/A

Develop Information

Active CompaniesZaklady Farmaceutyczne Polpharma SA
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsChoroidal Neovascularization +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A